{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Acnil by Jiangsu Chenpai Bond Pharmaceutical Co.,Ltd.
(2024)
Source URL:
First approved in 2024
Source:
Acnil by Jiangsu Chenpai Bond Pharmaceutical Co.,Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinidon-ethyl (BAS 615H) is a herbicide of isoindoldione class which selectively controls a wide spectrum of broadleaf weeds in cereals. Cinidon‐ethyl strongly inhibited protoporphyrinogen oxidase (Protox) activity in vitro, with I50 values of approximately 1 nM for the enzyme isolated from the weed species and from wheat. Cinidon-ethyl was approved in the EU in the early 2010s, but authorization was revoked due to lack of interest from the applicant.
Status:
Possibly Marketed Outside US
Source:
DR.HUI B-HA Multi Effect Repair Essence by Qingdao Huinorde Biotechnology Co., LTD
(2024)
Source URL:
First approved in 2024
Source:
DR.HUI B-HA Multi Effect Repair Essence by Qingdao Huinorde Biotechnology Co., LTD
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M019
(2024)
Source URL:
First approved in 2024
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Unknown by Shizuoka College of Pharmacy
Source URL:
First approved in 2024
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ligustrazine (tetramethylpyrazine) is a bioactive ingredient extracted from the widely-used Chinese herb, Chuanxiong. It inhibits of platelet aggregation, enhances of vessel dilation, increases cerebral blood flow and possesses neuroprotective properties. The injection solution of ligustrazine has been used especially in China to treat ischemic stroke, coronary heart disease, diabetic nephropathy, and knee osteoarthritis. Ligustrazine was also evaluated in clinical as a remedy for pressure sores, as a salvage agent for patients with non-Hodgkin's lymphoma, as a treatment for bronchial asthma and vertebrobasilar insufficiency.
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2024)
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M019
(2024)
Source URL:
First approved in 2024
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Efetozole is an antidepressant drug.